Stock Events

Stock Events

KADIMASTEM LTD NEW 

$3.75
0
-$0.08-2.09% Tuesday 21:00

Statistics

Day High
6.4
Day Low
6.4
52W High
9.07
52W Low
3.75
Volume
1,000
Avg. Volume
39,241
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30JunExpected
Q3 2019
Q1 2020
Q2 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
-0.19
-0.12
-0.06
0
Expected EPS
0
Actual EPS
-0.1058

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-7.25MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KMSTF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stem
STEM
Mkt Cap164.53M
StemCells, Inc. focuses on cell-based therapeutics, similar to Kadimastem's work in regenerative medicine, making them direct competitors in the stem cell therapy market.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap6.74M
Brainstorm Cell Therapeutics works on stem cell therapies for neurodegenerative diseases, directly competing with Kadimastem's ALS and MS treatments.
Mesoblast
MESO
Mkt Cap2.14B
Mesoblast Limited specializes in regenerative medicine using mesenchymal lineage cells, similar to Kadimastem's approach in cell therapy.
Vericel
VCEL
Mkt Cap1.77B
Vericel Corporation produces regenerative medicines for repairing damaged tissues, which aligns with Kadimastem's regenerative treatment strategies.
Biolife Solutions
BLFS
Mkt Cap1.34B
BioLife Solutions, Inc. provides biopreservation services for cells, which supports the cell therapy industry where Kadimastem operates.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is engaged in the development of programmed cellular immunotherapies, competing in the broader cell therapy market relevant to Kadimastem.

About

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.
Show more...
CEO
Mr. Ronen Twito CPA
Employees
11
Country
IL

Listings

0 Comments

Share your thoughts

FAQ

What is KADIMASTEM LTD NEW stock price today?▼
The current price of KMSTF is $3.75 USD — it has decreased by -2.09% in the past 24 hours. Watch KADIMASTEM LTD NEW stock price performance more closely on the chart.
What is KADIMASTEM LTD NEW stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange KADIMASTEM LTD NEW stocks are traded under the ticker KMSTF.
What were KADIMASTEM LTD NEW earnings last quarter?▼
KMSTF earnings for the last quarter are -0.11 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is KADIMASTEM LTD NEW revenue for the last year?▼
KADIMASTEM LTD NEW revenue for the last year amounts to 0 USD.
What is KADIMASTEM LTD NEW net income for the last year?▼
KMSTF net income for the last year is -7.25M USD.
How many employees does KADIMASTEM LTD NEW have?▼
As of April 02, 2026, the company has 11 employees.
In which sector is KADIMASTEM LTD NEW located?▼
KADIMASTEM LTD NEW operates in the Health Care sector.
When did KADIMASTEM LTD NEW complete a stock split?▼
The last stock split for KADIMASTEM LTD NEW was on April 08, 2024 with a ratio of 1:10.
Where is KADIMASTEM LTD NEW headquartered?▼
KADIMASTEM LTD NEW is headquartered in Ness Ziona, IL.